Replimune (REPL) Interest & Investment Income (2017 - 2026)
Replimune (REPL) posted Interest & Investment Income of $2.4 million for Q1 2026, down 16.76% sequentially from $2.8 million in Q4 2025, and down 59.69% YoY from $5.9 million in Q1 2025.
Analysis
Replimune (REPL) Interest & Investment Income (2017 - 2026) Analysis & Trends
Replimune has reported Interest & Investment Income for 9 years, with the latest figure at $2.4 million in Q1 2026.
- Quarterly Interest & Investment Income fell 59.69% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (down 35.48% YoY) and the FY2026 annual result came in at $13.6 million, down 35.49% from the prior year.
- Interest & Investment Income fell to $2.4 million in Q1 2026 per REPL's latest filing, from $2.8 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $6.2 million in Q2 2023 and troughed at $131000.0 in Q1 2022.
- A 5-year average of $4.0 million and a median of $4.7 million in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2026: Interest & Investment Income soared 4385.5% in 2023, then plunged 59.69% in 2026.
- Over 5 years, Interest & Investment Income stood at $2.7 million in 2022, then surged by 112.56% to $5.7 million in 2023, then retreated by 9.66% to $5.1 million in 2024, then slumped by 44.6% to $2.8 million in 2025, then decreased by 16.76% to $2.4 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $2.4 million, $2.8 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | 1.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.96 Mn |
| Mar 31, 2026 | 2.37 Mn |
| Dec 31, 2025 | 2.85 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 4.71 Mn |
| Mar 31, 2025 | 5.88 Mn |
| Dec 31, 2024 | 5.14 Mn |
| Sep 30, 2024 | 5.39 Mn |
| Jun 30, 2024 | 4.71 Mn |
| Mar 31, 2024 | 5.43 Mn |
| Dec 31, 2023 | 5.69 Mn |
| Sep 30, 2023 | 6.05 Mn |
| Jun 30, 2023 | 6.19 Mn |
| Mar 31, 2023 | 5.88 Mn |
| Dec 31, 2022 | 2.68 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | 343,000.00 |
| Mar 31, 2022 | 131,000.00 |
| Dec 31, 2021 | 87,000.00 |
| Sep 30, 2021 | 80,000.00 |